Suchergebnisse - "Herpes zoster"

PubPharm (8.823)

1

Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups : Data from active surveillance program. Puglia (Italy), 2021-23

enthalten in: Vaccine | 2024

von Stefanizzi, P. | Moscara, L. | Palmieri, C. | +5

2

Systemic therapy for psoriasis and the risk of cutaneous infections

enthalten in: The Journal of dermatology | 2024

von Higashi, Y. | Imafuku, S. | Tsuruta, N. | +2

3

Systematic Literature Review on the Incidence of Herpes Zoster in Populations at Increased Risk of Disease in the EU/EEA, Switzerland, and the UK

enthalten in: Infectious diseases and therapy | 2024

von Marijam, A. | Vroom, N. | Bhavsar, A. | +3

4

Serious neurological adverse events in immunocompetent children and adolescents caused by viral reactivation in the years following varicella vaccination

enthalten in: Reviews in medical virology | 2024

von Ramachandran, P. | Grose, C.

5

Herpes zoster (HZ) vaccine coverage and confidence in Italy : a Nationwide cross-sectional study, the OBVIOUS project

enthalten in: BMC infectious diseases | 2024

von Salussolia, A. | Capodici, A. | Scognamiglio, F. | +32

6

Herpes zoster (HZ) vaccine coverage and confidence in Italy: a Nationwide cross-sectional study, the OBVIOUS project

enthalten in: BMC infectious diseases | 2024

von Salussolia, A. | Capodici, A. | Scognamiglio, F. | +11

7

Neuralgia in the occipital region associated with ipsilateral trigeminal herpes zoster : Three case reports

enthalten in: Headache | 2024

von Nakaya, A. | Kaneko, K. | Miyazawa, K. | +4

8

Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population : Phase 1/2 Open-label Trial of Safety and Zoster Immunogenicity Evaluation for People With HIV With CD4 Counts Under and Above 300 Following Shingrix Vaccination and Healthy Volunteers (ZEUS)

enthalten in: ClinicalTrials.gov | 2024

9

A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants : A Phase 1, Randomized, Multicenter, Double-blind, Dose-ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants 50 to 69 Years Old

enthalten in: ClinicalTrials.gov | 2024

10

Nanopore sequencing in distinguishing between wild-type and vaccine strains of Varicella-Zoster virus

enthalten in: Vaccine | 2024

von Fukuda, Y. | Suzuki, T. | Iwata, K. | +7

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[883]